中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

302 records (took 0.028 seconds)

    Production of low-alcohol or alcohol-free beer with Pichia kluyveri yeast strains
    144.
    发明授权
    Production of low-alcohol or alcohol-free beer with Pichia kluyveri yeast strains 有权

    公开(公告)号：US10415007B2

    公开(公告)日：2019-09-17

    申请号：US15413246

    申请日：2017-01-23

    Applicant: Chr. Hansen A/S

    Inventor： Sofie Saerens ,  Jan Hendrik Swiegers

    IPC: C12C12/04 ,  C12C12/00

    Abstract: It has unexpectedly been found that a low alcohol or alcohol-free beverage, with a flavor profile very close to a beer of at least 4% (vol/vol) alcohol, can be produced by using Pichia kluyveri yeast strains. In particular, Pichia kluyveri yeast strains only use the glucose in the wort, and have the ability of converting this substrate into a high concentration of specific flavor compounds, which are normally produced by Saccharomyces ssp. yeast strains used for the brewing of beer. In this way the Pichia kluyveri yeast strains can be used to produce either a low alcohol or alcohol-free beverage, depending on the glucose levels in the wort. The main flavor compounds produced by Pichia kluyveri in the fermentation of wort are isoamyl acetate, isoamyl alcohol, ethyl butyrate, ethyl hexanoate and ethyl octanoate.

    Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis for use in prevention or treatment of upper respiratory tract infections
    146.
    发明授权
    Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis for use in prevention or treatment of upper respiratory tract infections 有权

    公开(公告)号：US10286018B2

    公开(公告)日：2019-05-14

    申请号：US15472754

    申请日：2017-03-29

    Applicant: Chr. Hansen A/S

    Inventor： Tracey Jane Smith

    IPC: A61K35/74 ,  A61K35/745 ,  A61K35/747 ,  A61K35/742

    Abstract: The present invention relates to a composition comprising Lactobacillus rhamnosus, preferably strain ATCC53103, and Bifidobacterium animalis subsp. lactis, preferably strain DSM 15954, for use in reducing the duration and/or severity of upper respiratory tract infection (URI) in teenagers and adults. Further aspects of the invention relate to a composition comprising Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis for use in increasing the Health-Related Quality of Life (HRQL) in teenagers and adults having upper respiratory tract infection (URI), for reducing at least one and preferably several such as two, three, four or all of the symptoms of sore throat, scratchy throat, cough, hoarseness, chest congestion and for reducing the median severity score in teenagers and adults having upper respiratory tract infection (URI).

    Probiotic Bifidobacterium adolescentis strains
    149.
    发明授权
    Probiotic Bifidobacterium adolescentis strains 有权

    公开(公告)号：US10022408B2

    公开(公告)日：2018-07-17

    申请号：US15504913

    申请日：2015-08-28

    Applicant: CHR. HANSEN A/S

    Inventor： Thomas Dyrmann Leser ,  Dorte Myling-Petersen ,  Jeffrey Earl Christensen ,  Anja Wellejus ,  Elke Brockmann

    IPC: A01N63/00 ,  A61K35/745 ,  A61K47/26 ,  C12R1/01

    Abstract: The present invention relates to novel isolated strains of Bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (TER) of a Caco-2 cell monolayer after 10 h treatment to more than 120% of TER at treatment start, ii) inducing secretion of >200 pg/ml of IL-10, and/or iii) inducing an IL-10:IL-12 ratio >1 when co-incubated with human PBMC derived dendritic cells. The strains may have one, two or all three of these capabilities. The present invention relates to the use of these novel strains for the in prevention, alleviation of symptoms, and treatment of diseases or conditions with an underlying impaired intestinal barrier function and pro-inflammatory activation of the mucosa. More specifically, the present invention relates to se of an isolated strain according to the invention for the prevention, alleviation of symptoms, or treatment of intestinal inflammatory conditions such as IBD and IBS, liver diseases such as NAFLD, NASH, cirrhosis, and alcohol-related liver disease, metabolic disorders such as metabolic syndrome, insulin resistance, type 2 diabetes, obesity, cardiovascular atherosclerosis, autoimmune diseases, such as celiac disease, type 1 diabetes, multiple sclerosis and rheumatoid arthritis, and mental conditions such as major depressive disorders, a mood disorder, a cognitive chronic fatigue syndrome, and anxiety.

Patent Agency Ranking